SCHEMBL4008089

SCHEMBL4008089

O=C(Nc1ccc(C(F)(F)F)cc1)Nc1ccccc1S(=O)(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
MAPT P10636 2/20 0.60
RAB9A P51151 2/20 0.60
HTT P42858 1/20 0.60
EPHX2 P34913 2/20 0.56
CA12 O43570 3/20 0.56
CA1 P00915 3/20 0.56
CA2 P00918 3/20 0.56
CA9 Q16790 3/20 0.56
ALDH1A1 P00352 1/20 0.52
POLB P06746 1/20 0.52
IDH1 O75874 1/20 0.52
STING1 Q86WV6 1/20 0.51
P2RY1 P47900 1/20 0.51
NPC1 O15118 1/20 0.50
TRPV1 Q8NER1 2/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
NAMPT P43490 1/20 0.48
GRIK1 P39086 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3346579 0.86 MAPT (0.68) MEN1KMT2AMAPTRAB9AHTT
SCHEMBL12010914 0.84 IDH1 (0.69) MEN1KMT2AMAPTRAB9AHTT
SCHEMBL12010909 0.82 MEN1 (0.60) MEN1KMT2AMAPTRAB9AHTT
SCHEMBL4009420 0.81 MAPT (0.63) MEN1KMT2AMAPTRAB9AHTT
SCHEMBL4548071 0.79 EPHX2 (0.85) MEN1KMT2AMAPTRAB9AHTT
SCHEMBL12010912 0.79 NR1H3 (0.68) MEN1KMT2AMAPTHTTEPHX2
SCHEMBL9486707 0.77 MEN1 (0.65) MEN1KMT2AMAPTRAB9AHTT
SCHEMBL5741984 0.76 TACR1 (0.64) MEN1KMT2AALDH1A1ABCC9ABCC8
SCHEMBL22588937 0.76 CA2 (0.49) MEN1KMT2AMAPTCA12CA1
SCHEMBL17102989 0.75 RAB9A (0.69) MEN1KMT2AMAPTRAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101516838-A Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS INC (US) 2009-08-26 CN claimed
US-20090197916-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS ARETE THERAPEUTICS, INC 2009-08-06 US claimed
US-20080207622-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-28 US claimed
US-20090197916-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS ARETE THERAPEUTICS, INC 2009-08-06 US disclosed
EP-2069294-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-06-17 EP disclosed
US-20080207622-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-28 US disclosed
WO-2008039999-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197916-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS EPHX1, NCEH1, PNLIP MEN1 3498/4885KMT2A 3363/4885MAPT 4632/4885
US-20080207622-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 MEN1 4253/4885KMT2A 3835/4885MAPT 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.